Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | ALDH1A2 | O94788 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506032 | 1.00 | RIPK1 (0.45) | RIPK1TSHRALDH1A1KDM4EMAOA | |
| SCHEMBL2581032 | 0.94 | RIPK1 (0.48) | RIPK1TSHRALDH1A1KDM4EHTT | |
| SCHEMBL4511395 | 0.82 | TSHR (0.48) | TSHRALDH1A1HTTP2RX7HCRTR1 | |
| SCHEMBL4511392 | 0.82 | TSHR (0.48) | TSHRALDH1A1HTTP2RX7HCRTR1 | |
| SCHEMBL4087896 | 0.82 | TSHR (0.48) | TSHRALDH1A1HTTP2RX7HCRTR1 | |
| SCHEMBL4511780 | 0.82 | TSHR (0.48) | TSHRALDH1A1HTTP2RX7HCRTR1 | |
| SCHEMBL2583972 | 0.82 | P2RX7 (0.39) | RIPK1TSHRALDH1A1HTTP2RX7 | |
| SCHEMBL4521177 | 0.82 | P2RX7 (0.39) | RIPK1TSHRALDH1A1HTTP2RX7 | |
| SCHEMBL4521180 | 0.82 | P2RX7 (0.39) | RIPK1TSHRALDH1A1HTTP2RX7 | |
| SCHEMBL4517482 | 0.80 | RIPK1 (0.43) | RIPK1TSHRALDH1A1KDM4EMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | RIPK1 4491/4885TSHR 4749/4885ALDH1A1 869/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | RIPK1 4491/4885TSHR 4749/4885ALDH1A1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.